• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immunity . Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus

tetano

Editor, Senior Moderator
Immunity


. 2022 Aug 6;S1074-7613(22)00339-9.
doi: 10.1016/j.immuni.2022.07.006. Online ahead of print.
Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus


Maya Sangesland[SUP] 1 [/SUP], Alba Torrents de la Peña[SUP] 2 [/SUP], Seyhan Boyoglu-Barnum[SUP] 3 [/SUP], Larance Ronsard[SUP] 1 [/SUP], Faez Amokrane Nait Mohamed[SUP] 1 [/SUP], Thalia Bracamonte Moreno[SUP] 1 [/SUP], Ralston M Barnes[SUP] 4 [/SUP], Daniel Rohrer[SUP] 4 [/SUP], Nils Lonberg[SUP] 4 [/SUP], Musie Ghebremichael[SUP] 1 [/SUP], Masaru Kanekiyo[SUP] 3 [/SUP], Andrew Ward[SUP] 2 [/SUP], Daniel Lingwood[SUP] 5 [/SUP]



Affiliations

Abstract

Human broadly neutralizing antibodies (bnAbs) targeting the hemagglutinin stalk of group 1 influenza A viruses (IAVs) are biased for IGHV1-69 alleles that use phenylalanine (F54) but not leucine (L54) within their CDRH2 loops. Despite this, we demonstrated that both alleles encode for human IAV bnAbs that employ structurally convergent modes of contact to the same epitope. To resolve differences in lineage expandability, we compared F54 versus L54 as substrate within humanized mice, where antibodies develop with human-like CDRH3 diversity but are restricted to single V[SUB]H[/SUB] genes. While both alleles encoded for bnAb precursors, only F54 IGHV1-69 supported elicitation of heterosubtypic serum bnAbs following immunization with a stalk-only nanoparticle vaccine. L54 IGHV1-69 was unproductive, co-encoding for anergic B cells and autoreactive stalk antibodies that were cleared from B cell memory. Moreover, human stalk antibodies also demonstrated L54-dependent autoreactivity. Therefore, IGHV1-69 polymorphism, which is skewed ethnically, gates tolerance and vaccine expandability of influenza bnAbs.

Keywords: B cell; antibody gene polymorphism; autoreactivity; broad; influenza virus; tolerance; universal; vaccine.
 
Back
Top Bottom